Pfizer Inc. (PFE) Position Cut by Tradition Capital Management LLC

Tradition Capital Management LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 38.8% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 18,516 shares of the biopharmaceutical company’s stock after selling 11,725 shares during the period. Tradition Capital Management LLC’s holdings in Pfizer were worth $657,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. AXA lifted its position in Pfizer by 9.2% during the fourth quarter. AXA now owns 5,188,453 shares of the biopharmaceutical company’s stock worth $187,926,000 after acquiring an additional 438,040 shares during the last quarter. SG Americas Securities LLC lifted its position in Pfizer by 3,116.6% during the fourth quarter. SG Americas Securities LLC now owns 1,186,121 shares of the biopharmaceutical company’s stock worth $42,961,000 after acquiring an additional 1,149,246 shares during the last quarter. Oldfield Partners LLP lifted its position in Pfizer by 33.1% during the fourth quarter. Oldfield Partners LLP now owns 109,850 shares of the biopharmaceutical company’s stock worth $3,979,000 after acquiring an additional 27,300 shares during the last quarter. Savant Capital LLC lifted its position in Pfizer by 4.4% during the fourth quarter. Savant Capital LLC now owns 54,941 shares of the biopharmaceutical company’s stock worth $1,990,000 after acquiring an additional 2,300 shares during the last quarter. Finally, Sawtooth Solutions LLC lifted its position in Pfizer by 195.3% during the fourth quarter. Sawtooth Solutions LLC now owns 53,196 shares of the biopharmaceutical company’s stock worth $1,926,000 after acquiring an additional 35,182 shares during the last quarter. Institutional investors and hedge funds own 69.45% of the company’s stock.

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Thursday, June 7th. They set an “overweight” rating and a $45.00 price objective for the company. Jefferies Financial Group set a $38.00 price objective on shares of Pfizer and gave the stock a “hold” rating in a research report on Friday, April 13th. BMO Capital Markets cut their price objective on shares of Pfizer from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Wednesday, May 2nd. Citigroup restated a “sell” rating on shares of Pfizer in a research report on Thursday, April 12th. Finally, Morningstar set a $43.50 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, May 2nd. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $40.27.

Shares of Pfizer opened at $36.33 on Tuesday, according to MarketBeat. The company has a market cap of $215.97 billion, a PE ratio of 13.71, a price-to-earnings-growth ratio of 1.80 and a beta of 0.93. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.45. Pfizer Inc. has a 12 month low of $32.32 and a 12 month high of $39.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.03. The business had revenue of $12.91 billion for the quarter, compared to analysts’ expectations of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period last year, the firm posted $0.69 earnings per share. equities analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, August 3rd will be paid a $0.34 dividend. The ex-dividend date of this dividend is Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a yield of 3.74%. Pfizer’s dividend payout ratio (DPR) is 51.32%.

In related news, EVP Laurie J. Olson sold 19,000 shares of Pfizer stock in a transaction that occurred on Wednesday, June 6th. The shares were sold at an average price of $36.45, for a total value of $692,550.00. Following the transaction, the executive vice president now directly owns 98,644 shares of the company’s stock, valued at $3,595,573.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 132,312 shares of Pfizer stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total transaction of $4,764,555.12. The disclosure for this sale can be found here. Insiders sold 156,535 shares of company stock worth $5,647,222 over the last three months. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply